As for SPHK1, it is known to induce EMT in hepatoma cells through the promotion of CDH1/ECADHERIN degradation [64], and thus, SPHK1-inhibitors could be a reasonable option against mesenchymal-like HCC. Here, CDH1 is linked to hepatocellular carcinoma.